CureVac

Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global advanced therapy medicinal products CDMO market is expected to reach USD 18.8 billion by 2030 and is expected to register a CAGR of 18.92% from 2024 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth.
  • Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.
  • In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Retrieved on: 
Wednesday, January 24, 2024

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.

Key Points: 
  • CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
  • The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
  • Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.
  • This project, along with its extensive pipeline, positions WestGene at the forefront of biopharmaceutical innovation and research.

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Retrieved on: 
Wednesday, January 24, 2024

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.

Key Points: 
  • CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
  • Renowned for her pivotal role in mRNA research, Dr. Xiangrong Song, co-founder and CEO of WestGene, presented the latest advances in the company's oncology sector, with a special focus on mRNA-based cancer vaccines.
  • The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
  • Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.

EQS-News: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Retrieved on: 
Friday, January 5, 2024

Both vaccine candidates are being developed in collaboration with GSK.

Key Points: 
  • Both vaccine candidates are being developed in collaboration with GSK.
  • Selected data can be reviewed in the presentation associated with this press release.
  • All three of the dose levels tested were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU.
  • “These positive Phase 2 data continue to strongly validate the competitiveness of our proprietary mRNA-technology platform and second-generation mRNA backbone in comparison to a licensed mRNA-based vaccine,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.

EQS-News: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Retrieved on: 
Tuesday, December 26, 2023

CureVac will appeal before the German Federal Court of Justice.

Key Points: 
  • CureVac will appeal before the German Federal Court of Justice.
  • The ruling represents a first decision on validity in ongoing patent litigation between CureVac and BioNTech SE in Germany, which involves a total of eight CureVac intellectual property rights.
  • “We consider the patent court’s decision unfortunate also in view of the positive preliminary opinion on EP 1 857 122 B1 the court provided earlier this year.
  • The decision is only one of many that will be made regarding the use of CureVac’s intellectual property in the development of Comirnaty®.

EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Retrieved on: 
Tuesday, December 26, 2023

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – November 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the third quarter and first nine months of 2023 and provided a business update.
  • Positive preliminary data reported in early 2023 in COVID-19 and flu provided strong validation of CureVac’s mRNA technology platform.
  • All jointly tested candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.
  • The first nine months of 2022 were positively impacted by €36.8 million related to the reversal of an outstanding CRO provision.

EQS-News: CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

Retrieved on: 
Tuesday, November 7, 2023

“Through the successful execution of Phase 1 and 2 studies, together with our partner GSK, we are on track to move our most advanced COVID-19 and seasonal flu programs forward into the later stages of clinical development,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.

Key Points: 
  • “Through the successful execution of Phase 1 and 2 studies, together with our partner GSK, we are on track to move our most advanced COVID-19 and seasonal flu programs forward into the later stages of clinical development,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.
  • In the joint seasonal flu development program, the first participant was dosed in the Phase 2 part of the combined Phase 1/2 study, following selection of a promising vaccine candidate based on positive Phase 1 interim data announced September 12, 2023 .
  • It was selected from the Phase 1 part of the study that compared a comprehensive series of multivalent, modified mRNA seasonal flu vaccine candidates with up to eight separate mRNA constructs per candidate.
  • In Phase 2, the selected candidate will be tested in younger and older adults at different dose levels compared to age-appropriate licensed seasonal flu comparator vaccines.

EQS-News: CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

Retrieved on: 
Thursday, September 28, 2023

A ruling on infringement will be provided latest once the validity of the intellectual property rights has been determined by the relevant patent offices.

Key Points: 
  • A ruling on infringement will be provided latest once the validity of the intellectual property rights has been determined by the relevant patent offices.
  • The validity of these intellectual property rights has been challenged by BioNTech.
  • “We are confident in the strength of our intellectual property portfolio and today’s decision indicates that the intellectual property rights at issue are infringed.”
    CureVac filed a patent infringement lawsuit in Germany against BioNTech in early June 2022.
  • Three additional intellectual property rights, added to the infringement lawsuit in July 2023, were not covered in the oral hearing.

EQS-News: CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

Retrieved on: 
Saturday, September 16, 2023

The Phase 1 part compared a comprehensive series of multivalent, modified mRNA seasonal flu vaccine candidates with up to eight separate mRNA constructs per candidate, addressing all four WHO-recommended flu strains.

Key Points: 
  • The Phase 1 part compared a comprehensive series of multivalent, modified mRNA seasonal flu vaccine candidates with up to eight separate mRNA constructs per candidate, addressing all four WHO-recommended flu strains.
  • The selected vaccine candidate will be advanced to the Phase 2 part of the study, which is expected to dose the first participant in Q4 2023 and will expand to include older adults aged 65 to 85.
  • Immunogenicity of all candidates was assessed in parallel with a licensed seasonal flu vaccine comparator.
  • The humoral responses observed supported the selection of a candidate vaccine for further evaluation in Phase 2 in younger and older adults.

EQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Retrieved on: 
Tuesday, August 22, 2023

“During the first six months of 2023, we continued building on the momentum from the strong start to the year.

Key Points: 
  • “During the first six months of 2023, we continued building on the momentum from the strong start to the year.
  • “Our unwavering commitment to innovation has enabled us to further expand our intellectual property portfolio, strengthening our mRNA technology ownership.
  • All jointly tested candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.
  • The first six months of 2022 were positively impacted by €21.3 million related to the reversal of an outstanding CRO provision.